Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Conduit swings to H1 loss amid elevated catastrophe claims

(Sharecast News) - Reinsurance firm Conduit traded lower early on Wednesday after it posted a H1 loss and slashed its return on equity expectations, citing elevated catastrophe claims and reserve increases linked to the ongoing conflict in Ukraine. Conduit swung to a $13.5m comprehensive loss in the six months ended 30 June, down from a $98.1m profit a year earlier, as its combined ratio ballooned to 122.1% from 85.7%.

The FTSE 250-listed firm highlighted that the California wildfires alone made up nearly a third of the loss ratio, while adverse reserve development following a UK High Court ruling on aviation losses tied to the Russian invasion of Ukraine added further pressure.

Conduit noted that despite an 8.9% rise in gross premiums written to $803.3m and a 3.9% investment return, its reinsurance service result sunk to a $15.2m loss, driven by higher claims and finance costs. Diluted losses per share came to $0.09, down from earnings of $0.62 per share twelve months earlier.

Looking ahead, Conduit now expects a mid-single-digit return on equity for 2025, down from prior guidance, but reiterated its medium-term target of mid-teens returns.

As of 0845 BST, Conduit shares had sunk 17.19% to 318.00p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.